Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)
Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –
Lakefront Biotherapeutics cash
Cash and short-term investments held at the end of each period.
Lakefront Biotherapeutics's cash was €87.87M at Dec 31, 2025. For fiscal 2025 it was €87.87M, up 36.8% from the year before. Over ten years it grew -12.7% a year on average. The highest annual figure on record is €2.23B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €87.87M | +36.8% |
| FY2024 | Dec 31, 2024 | €64.24M | -61.5% |
| FY2023 | Dec 31, 2023 | €166.80M | -67.2% |
| FY2022 | Dec 31, 2022 | €508.12M | -77.2% |
| FY2021 | Dec 31, 2021 | €2.23B | +4.6% |
| FY2020 | Dec 31, 2020 | €2.14B | +14.7% |
| FY2019 | Dec 31, 2019 | €1.86B | +44.2% |
| FY2018 | Dec 31, 2018 | €1.29B | +12.1% |
| FY2017 | Dec 31, 2017 | €1.15B | +18.3% |
| FY2016 | Dec 31, 2016 | €973.24M | +186.0% |
| FY2015 | Dec 31, 2015 | €340.31M | +81.3% |
| FY2014 | Dec 31, 2014 | €187.71M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | €87.87M | -96.1% |
| Q4 FY2024 | Dec 31, 2024 | €64.24M | -97.6% |
| Q4 FY2023 | Dec 31, 2023 | €166.80M | -92.2% |
| Q4 FY2022 | Dec 31, 2022 | €508.12M | -78.7% |
| Q4 FY2021 | Dec 31, 2021 | €2.23B | +20.0% |
| Q2 FY2021 | Jun 30, 2021 | €2.64B | +130.2% |
| Q4 FY2020 | Dec 31, 2020 | €2.14B | +65.4% |
| Q2 FY2020 | Jun 30, 2020 | €2.38B | +123.5% |
| Q4 FY2019 | Dec 31, 2019 | €1.86B | +61.7% |
| Q2 FY2019 | Jun 30, 2019 | €1.15B | -9.0% |
| Q4 FY2018 | Dec 31, 2018 | €1.29B | +32.6% |
| Q2 FY2018 | Jun 30, 2018 | €1.07B | +213.5% |
| Q4 FY2017 | Dec 31, 2017 | €1.15B | +513.3% |
| Q2 FY2017 | Jun 30, 2017 | €1.26B | – |
| Q4 FY2016 | Dec 31, 2016 | €973.24M | – |
| Q4 FY2015 | Dec 31, 2015 | €340.31M | – |
| Q4 FY2014 | Dec 31, 2014 | €187.71M | – |
See a number that looks wrong?